BioBAY微信订阅号
BioPOS微信服务号
Customers
×
The company focuses on the development and commercialization of vascular health products, including cardiovascular, cerebrovascular, peripheral blood tube and other consumables. The core team of the company is from well-known medical equipment companies, covering technology, production, quality, regulation, market and sales, and has a large number of industry elites. Through team self-financing and angel round financing, the company has received 8 million start-up funds for GMP plant construction and equipment procurement. The company's recent goal has been to promote the import substitution of several cardiovascular consumable products to the domestic market through independent research and development. Also preparing CE, FDA product registration, actively exploring overseas market. It is expected to acquire three categories of domestic registration certificates for clinical devices in 2018, and aim to obtain invention patents by 2018 to complete the patent layout of subsequent blockbuster products. The launch of the company's most important product in 2020 will bring more than 50 million revenue to the company, which will quickly occupy the market share of high-end interventional products in China.。
×
fully independent intellectual property rights of minimally invasive medical technology companies, and patented technology in the international leading position.R & D team is composed of cardiac surgeon Dr. Zhang Ji and a number of senior foreign professionals. The company's leading project is the development of innovative precision positioning heart valve implantation system technology and product development. The precise positioning system of heart valve implantation is a minimally invasive surgical technique, without thoracotomy, without extracorporeal blood circulation, can significantly reduce surgical trauma, shorten the patient's postoperative recovery time, reduce pain, reduce the patient's body condition, thereby expanding the range of indications, improve the therapeutic effect, reduce the the cost of surgery, the most in need of replacement heart valve patients can get treatment. This technology will change the traditional mode of operation, easier to operate and master, can simplify the process of heart valve replacement, reduce the doctor's requirements. Other similar products will require a doctor within the human heart valve implantation through the imaging ability, while products can completely rely on their own system of implant positioning device to complete the valve replacement operation, thereby reducing the risk of surgery, so that patients receive timely treatment. These advantages will help to reduce the overall cost of the national health care system, promote the reform of the medical system, reduce medical costs, save medical resources of the society, it will completely change the long-term dependence on imports of heart valve situation, help China minimally invasive medical technology to the world. In addition, the company will consolidate the existing advanced medical device research and development platform and production base for other related products R & D foundation.
×
The company has developed and produced "artificial joints of organic polymer materials", which is the first in the world and has a leading technology level in Europe and America. Based on bionics, through modifying to create a new type of artificial joints, solved the difficult problem (severe wear on joint face and instability, severe infection), greatly improve the reliability of artificial joint prostheses and prolong its service life. In addition, the core technology of PEEK dustless precise injection molding has greatly reduced the cost of products and broke the monopoly of multinational companies in artificial joint market. The company has applied for 35 domestic invention patents and utility patents covering hip, knee, shoulder and ankle joints, as well as 15 international PCT patents.
×
We are committed to the development and industrialization of all degradation stents for cardiovascular and cerebrovascular. At present, there are more than ten foreign companies producing coronary artery stent products in the world. Among them, the largest ones are Abbott , Medtronic and Boston. There are more than 10 enterprises in China to produce coronary artery stents, which account for 80% of the domestic market. Now late drug-eluting stents thrombosis incidence is low (about 0.7%), but after the occurrence mortality rate above 40%, therefore developing the degradation of coronary stents become the goal.
×
Established in 2007, CareRay Digital Medical System Co. is dedicated to the innovation and production of the newest generation of flat panel detectors for medical, veterinary, security and industrial digital X-ray imaging systems. Our R&D department and expansive production facility is located in the SuZhou Industrial Park in China. Our global sales office is located in San Jose, California, USA.With more than 120 employees, CareRay has grown to become a provider to global x-ray equipment manufacturers and distributors. CareRay excels at developing and manufacturing high-performance cesium iodide (CsI) direct deposition detectors and offers a complete line of sizes of fixed, portable and wireless models.CareRay’s award winning R&D team of experts has created more than a dozen significant technology patents, which CareRay uses to produce superior flat panel detectors for the global market.Through the pursuit of excellence, optimized engineering and disciplined fabrication processes, CareRay provides customers with advanced, robust, user-friendly flat panel detectors and software.
×
Molecular diagnostic kit is based on its high quality gold medal enzyme and multiple multicolor fluorescence quantitative PCR technology , having the characteristics of the following advantages: (1) the results reliable: closed tube detection, no product post-processing; Internal and external control, excluding false negative, false positive reaction; Sensitivity: accurate detection of mutated DNA with a low to 1% content; Sample savings: 1-3 tissue can meet multiple gene detection requirements at one time; Convenient operation: the whole process takes only 2-3 hours; The fluorescence PCR technology platform is suitable for large-scale screening. The detection of multiple target genes can be completed only one time.
×
Jousing Medical Co., Ltd. is an innovative, high-tech company focusing on cardiac defibrillation field of medical devices, providing products and total solution services for patients. The shareholders of the company are composed of not only experienced medical experts in cardiac defibrillation, academic authority of the equipment, but also professional manager with years of company operating experience. JThe product of Jousing Medical is currently in the R&D stage, and will enter upcoming clinical trials phase soon. Company Mission: With our professional and reliable service, providing a safe life support for patients with cardiac ventricular fibrillation.
×
The main products of the company is medical ultrasonic probes based on semiconductor technology. We are the only company in the world that has commercialized SiliconWaveTM technology. Semiconductor ultrasonic technology is far superior to existing piezoelectric ceramic (PZT) technology. In the field of medical imaging, it can be used to replace piezoelectric ceramic technology to further improve the performance and application range of medical image.
×
One high-tech medical laser company. Now in addition to innovation center at the Silicon Valley in the United States and China headquarters in Suzhou, offices in Beijing, Shanghai, Guangzhou, etc. The green laser operating system developed by realton has been certified by CFDA, and the product index reaches the international advanced level and has full intellectual property rights.
×
First Dimension BioSciences was founded in June 2015, and is located in the beautiful BioBay in Suzhou Industrial Park. First Dimension is a company working on quantifying life with big data genomics. Our mission is to utilize genomic information to improve public health. Starting with cancer genome profiling, we provide bioinformatics services in areas of cancer screening and early cancer detection, as well as clinical diagnosis and prognostic monitoring. We firmly believe that genomic information will be a powerful tool which can revolutionize our fight against cancer. First Dimension is comprised of a world-class, experienced R&D team, equipped with multiple platforms of high-end sequencing instruments, proven experimental and medical pipelines and a state-of-the-art computational data center. We are aiming to become an industry leader in big data genomics in China, and to that end, we are committed to building an authoritative genetic information database of cancer genomes and to establish a statistical compendium of Chinese mutation profiles.
×
Company focuses on optical coherence tomography (OCT) technology. OCT is a kind of penetrating 3D medical imaging technology, which can detect the scattered light of human tissue media and perform scanning on human tissues to generate three-dimensional images to reach the resolution of 10um. As a medical imaging technology, its main characteristic is penetrating power, and can provide high resolution. Due to the high spatial resolution, no X - ray radiation problem, also entering the body through the optical fiber, so it is especially applicable to cardiovascular system of three-dimensional imaging. The OCT system developed by Argus is mainly used to imaging the cardiovascular internal tissue and heart stents to provide intuitive image reference and relevant data for the diagnosis and treatment of coronary heart disease.
×
Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
×
ndoClot Plus, Inc. (EPI) is a privately founded company in Santa Clara, California. In collaboration with endoscopists and biomaterial scientists, EPI developed a breakthrough technology to control bleeding in the gastrointestinal tract (GIT) by spraying a unique and proprietary powder directly to the wound during endoscopy.the hemostatic powder directly to the wound during endoscopy. The EndoClot® Polysaccharide Hemostatic System (EndoClot® PHS)is being sold in Europe and other selected internatinal markets EndoClot® PHS consists of Absorbable Modified Polymers (AMP®) and a unique powder delivery system (applicator). EPI provides new therapeutic solutions to the world market for gastrointestinal (GI) endoscopy.
×
Suzhou Basecare Medical Device Co., Ltd. (hereinafter referred to as “Basecare”) is a leading high-tech enterprise invested by DaAn Gene Co., Ltd. [stock code: 002030]. Our team is committed to investigating products used for the clinical field of assisted reproduction while focusing on the development, sale, and service for preimplantation genetic screening (PGS). Since 2010, the core team began to provide high-throughput sequencing service and already set up an advanced big data platform for bioinformatic analysis. In 2013, the company tried to shift from the role of research and development to clinical services. Moreover, we collaborated with DaAn Gene to develop and register a high-throughput sequencing instrument “DA8600” and a no-invasive prenatal test (NIPT) Kit. Fortunately, “DA8600” has awarded “Medical Device Certificate” by China Food and Drug Administration (CFDA) [Reg. No. 20143401961]. From 2016, National Institutes for Food and Drug Control officially defined preimplantation genetic screening (PGS) as "Class III Medical Devices." The PGS kit independently developed by Basecare becomes the first PGS product approved "Special Approval Procedure for Innovative Medical Devices" by the Center for Medical Device Evaluation on May 13, 2016. At present, Basecare has applied for eleven patents in the field of assisted reproduction and seven software copyrights. Our company collaborated with Thermo Fisher Scientific to establish the “Reproductive & Genetic Clinical Research Center” in 2016. It means that we have ability to utilize the latest technology in clinical services to better meet the needs of scientific research, results transformation, and patients. Now we will devote ourselves to provide the best solutions for reproductive health, to help reduce the rate of birth defects, also to promote the popularization and clinical application of PGS/PGD technology in China.
×
Suzhou HighWire Medical Devices Co.,Ltd. (HighWire Medical) is specialized in interventional therapy devices area, our major products are all types of guide-wire. We have excellent R&D ability and powerful manufacturing ability thus to support our customers, and we will do OEM as well. HighWire Medical has many dedicated devices and processing technologies with independent intellectual property rights. Therefore, we are the high quality supplier for many local and abroad companies.
×
HOB Biotech Group (HOB) is one of China best IVD companies, with the focus on immunodiagnostic products. Especially for allergy & autoimmune disease diagnostics, HOB is the market leader in China. With our strong R&D capability and high quality manufacturing operation, HOB provides high quality products at very competitive prices to customers worldwide and keeps the market leader position in China. HOB is capable of manufacturing a very wide range of diagnostic products in our state-of-the-art facility. We are interested in forming a partnership with our OEM partners and willing to make custom-modifications of our products for you. We can supply our products on OEM conditions, tailor-made to fit your unique market needs. We can manufacture for you bulk products or ready-for-use kits in the design of our OEM partner, or any other format. If you are interested, please contact us. Quality assurance is the corner stone of our success. Our manufacturing site in Suzhou city is registered to ISO 13485 and complies with the requirement of SFDA for the in vitro diagnostics.  HOB manufactures diagnostic products of highest quality in full compliance with quality system standards (ISO 13485:2009). The most modern equipment operated by well-trained personnel guarantees the greatest reliability and lot-to-lot consistency. At all times compliance with relevant statutory, regulatory and legal requirements is ensured.One of the keys to our success is the continuous optimization of our comprehensive Quality Management System.
×
BioVention current focus is in the area of cardiovascular medical devices, especially drug-device combination products. The Company's production facilities include Class 10,000 and Class 100 clean rooms that meet the requirements for the manufacture of Class III medical devices in accordance with cGMP standards. The production site successfully passed a GMP audit by CFDA in March 2013. Huan Chen's first product, alpha stent - a sirolimus eluting coronary stent system, has followed the CFDA newly established clinical trial guidelines for drug eluting stent and completed the first vigorously controlled clinical trial with patient enrollment in excess of 1,000 (ASCENT Trial). Associated technologies have been granted multiple patents in the US (US7438925B2;US 8357386), China (03818546.6; 200680008362.9), and other countries. The Company has collaborated with 39 key hospitals in China, including Beijing University First hospital, Anzhen hospital, Chaoyang hospital, during ASCENT clinical trial and has established a solid ground in marketing the alpha stent going forward.
×
Mainly focus on the tumor gene detection field, engaged in vitro diagnostic reagents and related medical instrumentation development, production and sales, at the same time provide professional, personalized tumor precise testing services. Has three industry innovation technology: low frequency detection technology (ER - Seq) error correction algorithm (mTBI), the analysis of the molecular cloning technology (mClone), can be comprehensive reference from a new latitude for product research and development.
×
SceneRay Co., Ltd, a start-up medical company founded in 2009, focuses its efforts on the development of neuro-stimulation systems for the treatment of motion and psychiatric disorders, such as essential tremors, Parkinson's disease, Dystonia, depression, etc. SceneRay is currently working on the indication of Deep Brain Stimulation(DBS) for patents suffered from Parkinson's disease. DBS therapy is intended to electrically stimulate a specific part of the brain to control symptoms of Parkinson's disease(PD), such as tremor, rigidity, stiffness. SceneRay has completed multi-center human studies on the devices and the results confirm the safety and efficacy of the therapy. SceneRay has developed a comprehensive strategy to protect its IP. There are 86 patent applications have been filed in last 5 years including 2 PCTs. 26 applications were granted by China patent office.
×
Ryan Nano Medicine (Suzhou) Co., Ltd., founded in January 2012. Ryan Nano is a technology-oriented corporation that dedicates to the products of advanced medical catheters and life science reagents. Ryan Nano's technology platforms in related fields and the derived products reach the international leading level. The company first applied the concept of "Resistance to Adhesion-depositon of Bacterial Biofilm" and related platform technology to medical catheters in the worldwide, Another product of bio-consumables in world leading level developed by the company is a non-viral, synthetic high efficiency transfection reagent -- "MaxfectionTM". Until now, the company has been authorized 4 invention patents, and additionally 4 invention patents (international invention patents included) and 6 registered trademarks of the company and products are being submitted or under review.
×
NuHigh is focused on novel technologies and products to serve nucleic acid testing communities. NuHigh has been collaborating with Institute of Forensic Sciences (IFS) since NuHigh's birth. IFS' DNA Typer 15 is an example of such productive collaboration. DNA Typer 15 was the first human identification product developed in China. It, along with other products, has been used to build Chinese national forensic DNA database. In late 2011, Chinese forensic database surpassed United States to be the largest in the world. Now even a lot of county police department has established forensic DNA labs. All these promoted advance of forensic DNA technology and made it more widely used in crime investigation in China. NuHigh has a complete line of forensic DNA products including hot-start DNA polymerases, FRET labeled oligonucleotides, size standards, sample collection cards, and direct amplification reagents etc. All the products are made with cutting edge technologies. Besides continued effort in developing new forensic DNA technologies and products, NuHigh has begun to develop in vitro diagnosis (IVD) products. A GMP facility has been built as the result of such an effort. The facility will be approved for manufacturing of IVD products by CFDA later this year.
×
Suzhou SyMap Medical Ltd is located at Suzhou bioBAY as an innovative medical device company. The company is founded by an excellent team with outstanding reputation and exceptional experience in cardiovascular medical device field in both China and US. SyMap is dedicated to developing a proprietary catheter-based renal mapping and ablation system for renal denervation therapy to treat hypertension and other diseases, such as heart failure, arrhythmia, renal failure, diabetics and sleep apnea, etc. Our novel renal mapping and ablation technology optimizes the delivery of renal denervation, significantly improves responder rate to the therapy, and can be also used to assess whether an efficient ablation is delivered for renal sympathetic denervation. The unique position of SyMap in renal denervation field is protected by a portfolio of IPs (pending), and the proprietary technology platform of SyMap has been granted with USA CRT2012 Best Innovation Award.
×
Suzhou InnoMed Medical Device Co., Ltd. is a high-tech implantable medical device designer and manufacturer and OEM service provider. The company has a renowned technical team in implantable medical device industry and owns several world-leading proprietary technologies including surface fine processing of nitinol devices, shape-setting of nitinol wires, AAA/TAA graft, peripheral braided stent and non-destructive Af temperature measurement instrument. The company's chairman and president Dr Xiaoyan Gong is awarded 2012 Suzhou Industrial Park Leading Talent. Moreover, the company has filed ten Chinese patents, four of which has been granted. A few government funding projects, such as "Haiou Project" and "Gusu Talent Project", are under application. Together with other fellow companies, the company wishes to make contributions to boosting implantable medical device technology and social healthcare in China.
×
NeuInvent Inc. (Suzhou) is rooted from NeuroInvent Inc.(US) which is a California Silicon Valley based medicaldevice company. Its core members are group of physician scientists from thefield of neurophysiology, neurology and neurosurgery. Company’s innovationalproducts focus on improving surgical accuracy in operating nerve systemsincluding neurosurgeries, orthopedic surgeries, ENT, and rehab, etc.,especially minimal invasive surgeries. Our products are clinical drivencombining with high technology and superior user experience. NeuInvent Inc. (Suzhou) is aiming on a growingmarket in China that urgently needs its own innovational medical devices in aleading position in national and global market. NeuInvent Inc. (Suzhou) is bringing new model of neural functional monitoring system and patented surgical devices intoChina market.
×
Genesky Diagnostics (Suzhou) Inc.,Ltd specializes in gene analysis technology development and clinical molecular diagnosis, we not only developed a series of genetic screening and diagnosis kits or testing services by using our self-developed core technology, but also provide gene analysis services based on our patented technology with various domestic and foreign research institutes together. Our company is well-known for our self-developed international leading innovative gene analysis technology. We are excellent provider for genetic analysis research services and clinical molecular genetic diagnosis kits or detection services. Our main products are multiple gene point mutation and/or gene copy number rapid detection kits based on our patented technology of multiple gene analysis (PCT/CN2011/074613, including SNPscanTM and CNVplex®). The main kits currently being developed include, common microdeletion / duplication syndrome rapid molecular diagnosis kit, Chinese thalassanemia related common gene mutation screening kit, Chinese deafness related common gene mutation screening kit, spinal muscular atrophy detection kit, human 24 chromosomes abnormality detection kit, et al.
×
Visunex Medical Systems Co. was found in April 2013 which is a wholly foreign-owned high-tech medical device enterprise. The professional team consists of the world class experts in the advanced technologies for optics, mechanics and products design, and the branding operation executives from some of the world's top 500 enterprises. The Company owns fundamental intellectual property rights and patented technology for its products, with solid support and reputation for innovation among the medical professionals. The company is expected to be the global leader in ophthalmic equipment market in a few years. The patent imaging technology solved the problem of image fuzzy of the dark eyes, which enable races from Asia, Africa, South America and South Europe to be screened. The main patent technology includes: Micro optical and mechanical system design; Micro devices and solid-state lighting technology; medical data transmission & storage; Standards and methods for remote diagnosis; Medical software management system. In light of the urgent need of neonatal screening around the world, Visunex focus on the design, manufacture and sell for the new type wide-field fundus imaging system and data serving network. The 2500 square meters research and production base has been found in SIP and the production facilities specification requirements are ready for FAD-GMP approval. The company has won the honorary title of science & technology leader in SIP, which getting the strong support of central and local governments. The current product PanoCam LT is a portable wide-field fundus imaging system. It is the only instrument for optical screening around the world now. The product contains 100% intellectual property rights and patents, which are the world leading technology.
×
PIC designs and manufactures lasers and laser modules for instrumentation applications dominantly for biotechnology, but also for other application areas. We offer CW solid-state lasers covering the UV, visible and IR wavelength range and specialize in the delivery of photons the way our customers need them. Our value to our customers is to use our expertise in lasers and laser modules to provide a high level of integration. The benefits to our customers are: Streamlined supply chain 、Manufacturing cost reduction 、Faster design cycles 、New instrument designs.
×
ET Healthcare (Suzhou) was established on May 8, 2012. The ET team has successful startup experience, including research and development, manufacturing, marketing and sales of many world-class products. We have developed a proprietary immunoassay technology. The intellectual property consists of a novel detection technique, nano-materials, automation, analytical software, reagents, etc. The analyzers and the reagents based on this technology can achieve the state-of-the-art performance, with potential applications in point-of-care testing as well as high throughput analysis. The test menu includes cardiac diseases, inflammation, tumors, and etc. We were granted the manufacturing permits for Class III IVD instruments and Class II reagents in January 2013. We have received the approvals for two analyzers in May 2014 and expect multiple reagent approvals in June 2014.
×
Xukon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, kon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate and comprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Xukon will continue to interpret the code of life and bring people the hope and joy of life. Nucleic acid analytical platforms such as real-time qPCR, microarray and next-generation sequencing often require starting samples to meet specific quantity and quality threshold to generate reproducible and accurate data. These minimal sample requirements in quantity and quality are not easily achieved in many applications, especially in the field of forensics and IVD. Extremely tiny samples such as single cells, plasma, hair follicle, blood stain, fine-needle aspiration and laser capture micro-dissection are often severe challenges for all genetic assays regarding detection of point mutation, copy-number variations, indels, gene fusions and expression. These challenges may cause failure or poor reproducibility of the results. MALBAC® technology is the most powerful tool to overcome these challenges up to date. By virtue of unprecedented evenness in amplification, MALBAC® technology is able to amplify trace amount (even single chromosome) nucleic acids to millions fold, thus make ever impossible assays practicable.
×
以诺康医疗科技(苏州)有限公司成立于2014年6月,注册资金1000万人民币,在苏州和美国加州建立面积近500平方米的研发实验室,并在苏州建有1000平方米GMP生产车间。公司拥有世界一流的超声手术设备和系统(包括超声手术刀系统,白内障超声乳化手术系统)的研发团队及核心技术,具有自主知识产权,已申请19项专利,3项发明专利和9项实用新型专利已经授权,5项发明专利和2项PCT等待授权,更多国内专利及PCT专利将准备提交。公司创始人均有美国博士学位以及多年的在国外大公司和高科技企业的任职经历,公司目前已有10余位高素质研发人员,均毕业于国内外知名院校(包括加州大学,清华大学,中国科技大学,复旦大学等)。创始人骆威博士获2014年苏州工业园区第八届科技领军人才称号和2015年苏州市姑苏创业领军人才称号。
我们团队所拥有的技术具有高度的先进性和完整性,并且在超声能量控制、超声手柄、 超声刀头、及玻璃体切割等方面具有革命性的原始创新(如按需分配的超声能量模式、新型扭转手柄、超声玻璃体切割,并已申请专利保护),能够开发出世界领先的超声刀和白内障超声手术产品,从而不仅实现超声手术器械的国产取代进口,而且能与国际厂商在全球市场进行竞争。目前已完成超声刀原型机开发和超乳手术系统的超声子系统和手柄等的开发,2017年将完成超声刀临床试验并进行三类有源器械注册证申报以及CE认证。
公司的短期目标是打造超声刀和白内障超声乳化手术产品的民族品牌,打破国外巨头(Johnson 强生,Alcon爱尔康,AMO 眼力健等)对国内超声刀和高端白内障手术器械的垄断地位,实现国产替代进口,成为国内市场份额的主要占有者之一。中期目标是产品线扩大到其他高端眼科及超声手术产品(如超声外科吸引手术设备及超声骨科手术设备),成为我国乃至更大范围内的超声手术器械市场的主要份额占有着之一。远期目标是成为高端眼科和超声手术产品的旗舰企业,以庞大的国内市场和发展中国家市场作为依托,与国际厂商竞争全球市场。
×
InTec PRODUCTS, INC., solely owned by the HongKong ITH Group, was established in 1989. InTec PRODUCTS, INC. is a professional biotech company that specializes in research & development, manufacturing and distribution of the medical diagnostic products. Thanks to the supports from our valued customers worldwide, InTec PRODUCTS, INC has become one of the most successful diagnostic companies in the world. After several years’ fruitful construction, InTec's operations now include Beijing Life Science Research Center, SuZhou SIP Biotechnology Center and Xiamen office, which covers an area of 30,000 square meters of modern GMP standard factory. Further, InTec also was the first Chinese IVD manufacturer to obtain the certification for ISO9000, ISO13485.